Asarfi Hospital Limited · BSE:ASARFI
Asarfi Hospital — Q3 FY2025 Earnings Presentation
19 slides from Asarfi Hospital's earnings presentation, Jan 31, 2025
Slide 1: Asarfi Hospital Limited - BSE Investor Presentation Cover Letter
असफ हॉ ीटल सबके िलए ा AHL/AO/2025/746 Date: 31.01.2025 To The BSE Limited The Listing Department 25th Floor, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001 Sub: Investor Presentation Ref: - Scrip Code: 543943 Dear Sir/ Ma’am, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Dis
Slide 2: Investor Presentation Q3 FY2025
Investor Presentation Q3 FY2025
Slide 3: Asarfi Hospital: At a Glance
Asarfi Hospital : At a Glance Asarfi Hospital Limited (AHL), Established in 2008, is a key multi-specialty tertiary healthcare service provider in the Dhanbad Area which was founded and managed by first-generation entrepreneurs Mr. Harendra Singh, Mr. Nayan Prakash Singh, and Mr. Udai Pratap Singh.
Slide 4: Departments and Facilities
Departments and Facilities General Paediatrics & General Cardiology Neurosciences Obstetrics & medicine Neonatology Surgery Gynaecology Gastroenterology Orthopaedics Burn & Plastic Oncology Nephrology Urology Surgery Ophthalmology ENT Day Care Dental Sciences Physiotherapy Emergency services Nutriti
Slide 5: Asarfi's New Cancer Institute
Asarfi’s New Cancer Institute • With a mission to provide comprehensive, state-of-the-art cancer care with a holistic approach that encompasses medical expertise, emotional support, and cutting-edge technology, Asarfi Hospital laid down the foundations for the construction of its new Cancer Institut
Slide 6: Board of Directors & Key Managerial Personnel
Board of Directors & Key Managerial Personnel Harendra Singh Udai Pratap Singh Sukanti Kumar Das Promoter & CFO Promoter and MD Non- Executive Director • A visionary entrepreneur inspired by the • Renowned Consultant Gynaecologist Company’s Purpose—Health for All. • Started his career in 2017, he is
Slide 7: Consolidated Key Achievements (1/2)
Consolidated Key Achievements Half-Yearly – Q3’FY25 Performance (1/2) (H1’FY25) ➢ Revenue from Operations: In Q3 FY25, the Company reported revenues of ₹ 3,289 lakhs, marking a 64% increase compared to ₹ 2,005 lakhs in Q3 FY24. ➢ Patient Volume: The number of patients served rose by 38% year-over-ye
Slide 8: Consolidated Key Achievements (2/2)
Consolidated Key Achievements Half-Yearly – Q3’FY25 Performance (2/2) (H1’FY25) ➢ Strategic Partnerships: MoU with DVC: Signed a Memorandum of Understanding with Damodar Valley Corporation (DVC) to provide exclusive cashless treatment to DVC employees. ➢ This partnership is expected to increase the
Slide 9: Performance Highlights (Standalone) – Q3'FY25
Performance Highlights (Standalone) – Q3’FY25 Total Income(₹ in Lakhs EBITDA (₹ in Lakhs) 4,000 900 25% 3,500 800 24% 24% 3,000 700 24% 23% 2,500 600 23% 500 23% 2,000 400 22% 1,500 300 22% 1,000 200 21% 500 100 21% 2,125 3,378 520 787 0 0 20% Q3FY24 Q3FY25 Q3FY24 Q3FY25 Total Income EBITDA EBITDA M
Slide 10: Performance Highlights (Consolidated) – Q3'FY25
Performance Highlights (Consolidated) – Q3’FY25 Total Income(₹ in Lakhs EBITDA (₹ in Lakhs) 4,000 900 25% 3,500 800 24% 24% 3,000 700 24% 600 23% 2,500 23% 500 23% 2,000 400 22% 1,500 300 22% 1,000 200 21% 500 100 21% 2,125 3,378 520 785 0 0 20% Q3FY24 Q3FY25 Q3FY24 Q3FY25 Total Income EBITDA EBITDA
Slide 11: Financial Performance Highlights (Standalone) – Q3'FY25
Financial Performance Highlights (Standalone) – Q3’FY25 Profit & Loss (₹ in Lakhs) Balance Sheet Items (₹ in Lakhs) Q3 Q3 Y-o-Y 9M 9M Y-o-Y Particulars FY24 FY24 FY25 Growth FY24 FY25 Growth Net Worth 7,761 Total Income 2,125 3,378 59% 6,244 8,937 43% 8,607 Borrowings 4,819 EBITDA 520 787 51% 1,418
Slide 12: Financial Performance Highlights (Consolidated) – Q3'FY25
Financial Performance Highlights (Consolidated) – Q3’FY25 Profit & Loss (₹ in Lakhs) Balance Sheet Items (₹ in Lakhs) Q3 Q3 Y-o-Y 9M 9M Y-o-Y Particulars FY24 FY24 FY25 Growth FY24 FY25 Growth Net Worth 7,739 Total Income 2,125 3,378 59% 6,244 8,937 43% 8,607 Borrowings 4,819 EBITDA 520 785 51% 1,41
Slide 13: Operational Performance Highlights – Q3'FY25
Operational Performance Highlights – Q3’FY25 Surgery Count and Y-o-Y Growth Operational Performance Department Q3 FY24 Q3 FY25 Y-o-Y Growth Particulars Q3 FY24 Q3 FY25 Y-o-Y Growth General Surgery 141 198 40% In-Patient (Nos.) 2,345 3,324 42% Obs & Gyn 95 149 57% Out Patient (Nos.) 12,623 16,581 31%
Slide 14: Revenue Mix Q3'FY25 Vs Q3'FY24 (Hospital Vertical)
Revenue Mix Q3’FY25 Vs Q3’FY24 (1/2) Hospital Vertical Cardiology Neurosciences 5.0% General Medicine 5.0% 1.6% Paediatrics & Neonatology 1.6% 0.9% General Surgery 0.9% 27.6% 4.9% 27.6% Obstetrics & Gynaecology 4.9% Orthopaedics Pulmonology Oncology 5.6% Urology 5.6% Department-wise Gastroenterology
Slide 15: Revenue Mix Q3'FY25 Vs Q3'FY24 (New Cancer Institute)
Revenue Mix Q3’FY25 Vs Q3’FY24 (1/2) New Cancer Institute Vertical Medical Oncology 2% 4% 2% 4% Surgical Oncology 13% 13% Radiation Oncology Medical Officer Radiology Department-wise Head and Neck Oncology Department-wise Revenue Mix Q3’FY24 Revenue Mix Q3’FY25 Haemato-Oncology Dialysis 56% 58% 22%
Slide 16: Operational Highlights – Q3'FY25 (2/2)
Operational Highlights – Q3’FY25 (2/2) IPD-OPD Volumes IPD-OPD Revenues (In Rs. Lakhs) 1,00,000 89,087 8,000 7,081 90,000 7,000 80,000 70,868 6,128 65,563 6,000 5,628 70,000 60,000 5,000 50,000 4,000 40,000 2,679 3,000 30,000 16,581 2,000 1,379 1,582 20,000 9,554 12,623 942 7,503 8,036 840 10,000 2,
Slide 17: Competitive Strengths
Competitive Strengths Experienced & highly qualified Regional team of medical Advantage professionals Advanced high-end Track record of stable medical equipment operating and financial and Technology performance ✓ Equipped with ✓ Stable operating and cutting-edge financial performance ✓ AHL boasts a
Slide 18: Expansion Plans
Expansion Plans ❑ Introduction of an ❑ Establishment of a ❑ Launch of educational ❑ Strategic capacity IVF vertical in the Bone Marrow courses in law, BCA, expansion: Increasing existing hospital, Transplant unit in the and medical fields, bed capacity in the catering to cancer hospital, leveraging
Slide 19: Disclosure and Contact Details
Disclosure and Contact Details Certain matters discussed in this presentation may contain statements regarding the company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements do not guarantee future performanc